Artivion, Inc. (FRA:CYL)
Germany · Delayed Price · Currency is EUR | Market Cap | 879.50M -22.2% |
| Revenue (ttm) | 397.82M +17.6% |
| Net Income | 10.13M |
| EPS | 0.21 |
| Shares Out | n/a |
| PE Ratio | 86.84 |
| Forward PE | 40.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 17.50 |
| Previous Close | 18.00 |
| Day's Range | 17.50 - 17.50 |
| 52-Week Range | 17.50 - 41.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Artivion
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branc... [Read more]
News
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs
New York, May 21, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOY...
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY, MAAY, NUGY, SEMY, QBY, RGYY, HMYY, RTYY, MUYY, TMYY, CWY, CRY and 20+ Others
New York, May 21, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOY...
Endospan announces Artivion closed the transaction to acquire the company
Endospan announced that Artivion (AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration PMA approval of the NEXUS…
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction ...
Artivion Completes Acquisition of Endospan Ltd.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing ...
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and Big Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Artivion ($AORT), Viant Technology ($DSP), and RealReal ($REAL) as companies with solid f...
Artivion price target lowered to $44 from $58 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Artivion (AORT) to $44 from $58 and keeps a Buy rating on the shares.
Artivion price target lowered to $45 from $55 at Lake Street
Lake Street lowered the firm’s price target on Artivion (AORT) to $45 from $55 and keeps a Buy rating on the shares. The guidance pulldown on lower-than-anticipated Stent growth was…
Artivion price target lowered to $38 from $50 at Oppenheimer
Oppenheimer lowered the firm’s price target on Artivion (AORT) to $38 from $50 and keeps an Outperform rating on the shares following quarterly results. The firm highlights that Endospan acquisition…
Artivion price target lowered to $45 from $55 at Stifel
Stifel lowered the firm’s price target on Artivion (AORT) to $45 from $55 and keeps a Buy rating on the shares.
Artivion price target lowered to $36 from $48 at Canaccord
Canaccord lowered the firm’s price target on Artivion (AORT) to $36 from $48 and keeps a Buy rating on the shares. The firm said Artivion’s Q1 revenue missed expectations, and…
Artivion price target lowered to $48 from $53 at Citizens
Citizens lowered the firm’s price target on Artivion (AORT) to $48 from $53 and keeps an Outperform rating on the shares. The company lowered full-year constant-currency sales growth guidance by…
Artivion reports Q1 non-GAAP EPS 8c, consensus 12c
Reports Q1 revenue $116.3M, consensus $115.74M. “In Q1 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver ...
Artivion lowers 2026 revenue view to $480M-$496M from $486M-$504M
2026 revenue consensus $495.28M. Lowers 2026 adjusted EBITDA view to $100M-$107M from $105M-$110M.
Artivion Earnings Call Transcript: Q1 2026
Q1 2026 saw 12% revenue and 26% adjusted EBITDA growth, led by On-X and stent grafts, but international softness and AMDS set sales timing prompted a guidance reduction. Endospan acquisition and NEXUS launch are set to expand the aortic arch portfolio and drive future growth.
Artivion Earnings release: Q1 2026
Artivion released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Artivion Slides: Q1 2026
Artivion has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Artivion Quarterly report: Q1 2026
Artivion has published its Q1 2026 quarterly earnings report on May 7, 2026.
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12...
Artivion Slides: Corporate presentation
Artivion has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
GraniteShares Expands YieldBOOST(TM) Lineup with Launch of CRY and XEY ETFs
New YieldBOOST TM ETFs Tied to Circle Internet Group and Ether NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- GraniteShares, an ETF issuer specializing in high-conviction and income-oriented ETFs, today...
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results...
Artivion added to Conviction List at Needham
Needham added Artivion (AORT) to the firm’s Conviction List while maintaining a Buy rating and $58 price target Artivion is int he middle of a product cycle driven by its…
Artivion upgraded to Buy from Neutral at Ladenburg
Ladenburg analyst Jeffrey Cohen upgraded Artivion (AORT) to Buy from Neutral with a $42 price target
Artivion’s PMA for Nexus Aortic Arch System approved by the FDA
Artivion (AORT) announced that the FDA has approved the premarket approval application, or PMA, for the Nexus Aortic Arch System, developed by Endospan, Artivion’s partner. The approval entitles Artiv...